Q-omics provides the consensus-scored CACNG1 profile across patient tissues and cancer cell-line models. CACNG1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, CACNG1 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, CACNG1 RNA expression shows 13,399 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SCLC, BRCA, and HNSC as cancer lineages where CACNG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNG1 survival associations across molecular data types. CACNG1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNG1 RNA expression–survival associations across cancer types. High CACNG1 expression shows unfavorable associations in HNSC, KIRP and KIRC, but favorable associations in SCLC, CESC and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for CACNG1 RNA expression.
This table summarizes CACNG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CACNG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNG1 shows lower tumor expression in LUSC, LUAD, HNSC and PRAD and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher CACNG1 RNA expression in tumor versus normal tissue (log2 FC = +1.164, t-test p < 0.001).
This table shows molecular features associated with CACNG1 in patient tissues and cancer cell lines. In patient samples, CACNG1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
